Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARA trial of tirzepatide and letrozole in postmenopausal hormone receptor-positive breast cancer
2026-525820-76-00Phase 2Authorised
- Sponsor
- UZ Leuven
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tirzepatide and letrozole in breast cancer, obesity and Overweight (3 arms), sponsored by UZ Leuven. Primary endpoint: Mean change in log-transformed Ki67 expression. Planned start Aug 2026; status: authorised.
02
Drugs
tirzepatideletrozole
03
Conditions
breast cancerobesityOverweight
Beyond the preview
Go deeper on 2026-525820-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525820-76-00.